| Name | Title | Contact Details |
|---|
Zura Bio is a clinical stage biotechnology company focused on developing ZB 168, an anti IL7Rα inhibitor, for the treatment of alopecia areata and other inflammatory diseases.
"Taro Pharmaceuticals U.S.A., Inc., and its divisions, subsidiaries and affiliates (collectively, ""Taro"") operate a variety of websites designed to provide you with services ranging from valuable health resources to corporate news and product information"
Harendorf Technolgy is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Harvard Drug Group is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.